UK Biotech Defies Pandemic, On Course For Record Fundraising Year
But IPO Number Still Low
Executive Summary
The UK’s biotech sector sees investor interest surge during the pandemic, though IPO levels are still disappointing compared with recent years.
You may also be interested in...
Synairgen Supercharges R&D With $100m Financing
With a candidate COVID-19 therapy in clinical development, the UK’s Synairgen has raised $101m on the UK’s AIM to support clinical studies and manufacturing plans.
Two New Biotechs Spin Out From Edinburgh’s Regenerative Medicine Centre
Scotland’s investment in regenerative medicine is paying off with two promising start-ups, one targeting liver disease, the other oncology, launching within days of each other.
Investor Faith In David Hung’s Nuvation Renewed By Anheart Buyout
The acquisition brings two potential best-in-class cancer therapies, which could make Nuvation a commercial company as soon as 2025.